Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO 25-6981
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intrathecal (in Preclinical And Research Settings)
01
Overview
RO 25-6981 is a potent and highly selective, activity-dependent antagonist of N-methyl-D-aspartate (NMDA) receptors containing the GluN2B (previously NR2B) subunit. It displays over 5000-fold selectivity for GluN1C/GluN2B over GluN1C/GluN2A subunit combinations, with IC50 values in the low nanomolar range. RO 25-6981 exhibits neuroprotective, anti-convulsant, antidepressant, and anti-inflammatory effects in preclinical models, and is often used in research on neuroprotection, depression, epilepsy, and neuropathic pain. It is not approved for human therapeutic use and is used primarily for research purposes. The compound was developed by F. Hoffmann-La Roche as a tool compound for neuroscience research[1][2][3][4][5][7][8].
- Other names
- RO 25-6981 maleateRO25-6981 maleateRO-25-6981 maleate
02
Targets
GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)
Beyond the preview
Go deeper on RO 25-6981.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO 25-6981.